Literature DB >> 1917033

Hepatitis C virus antibodies among risk groups in Turkey.

I Köksal1, K Biberoğlu, S Biberoğlu, F Koç, Y Ayma, F Aker, H Köksal.   

Abstract

In order to determine the prevalence of hepatitis C virus (HCV) infection in the Black Sea region in Turkey, 287 serum samples taken from risk groups were investigated for anti-HCV antibodies using HCV EIA system. Anti-HCV antibodies were found to be positive in 51.2% of chronic haemodialysis patients, 20.6% of probable acute non-A, non-B hepatitis patients, 4% of patients who had multiple blood transfusions, 1.5% of the health personnel, while in new haemodialysis patients anti-HCV antibodies were not found.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1917033     DOI： 10.1007/bf01644950

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  8 in total

1.  The prevalence of hepatitis C virus antibodies among hemodialysis patients.

Authors:  J B Zeldis; T A Depner; I K Kuramoto; R G Gish; P V Holland
Journal:  Ann Intern Med       Date:  1990-06-15       Impact factor: 25.391

2.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

3.  Virology without virus?

Authors:  R Laufs
Journal:  Infection       Date:  1990 Nov-Dec       Impact factor: 3.553

4.  Antibodies to hepatitis C virus.

Authors:  M Roggendorf; F Deinhardt; R Rasshofer; J Eberle; U Hopf; B Möller; R Zachoval; G Pape; W Schramm; F Rommel
Journal:  Lancet       Date:  1989-08-05       Impact factor: 79.321

Review 5.  Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis.

Authors:  Q L Choo; A J Weiner; L R Overby; G Kuo; M Houghton; D W Bradley
Journal:  Br Med Bull       Date:  1990-04       Impact factor: 4.291

6.  Hepatitis C virus antibodies among risk groups in Spain.

Authors:  J I Esteban; R Esteban; L Viladomiu; J C López-Talavera; A González; J M Hernández; M Roget; V Vargas; J Genescà; M Buti
Journal:  Lancet       Date:  1989-08-05       Impact factor: 79.321

7.  Outbreak of non-A, non-B hepatitis in centre haemodialysis patients: a retrospective analysis.

Authors:  D Marchesi; C Arici; E Poletti; G Mingardi; E Minola; G Mecca
Journal:  Nephrol Dial Transplant       Date:  1988       Impact factor: 5.992

8.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728
  8 in total
  3 in total

Review 1.  Potential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa: an analysis using hepatitis C virus as a proxy biomarker.

Authors:  Yousra A Mohamoud; F DeWolfe Miller; Laith J Abu-Raddad
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

2.  Treatment of hepatitis C in hemodialysis patients using pegylated interferon alpha-2a in Turkey.

Authors:  Sukran Kose; Alp Gurkan; Fatih Akman; Mehmet Kelesoglu; Ufuk Uner
Journal:  J Gastroenterol       Date:  2009-03-11       Impact factor: 7.527

3.  The epidemiology of hepatitis C in Turkey.

Authors:  D L Thomas; R W Mahley; S Badur; E Palaoglu; T C Quinn
Journal:  Infection       Date:  1994 Nov-Dec       Impact factor: 3.553
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.